Ensign Peak Advisors, Inc Prothena Corp Public LTD CO Transaction History

Ensign Peak Advisors, Inc

$56.1 Billion
Q3 2024

A detailed history of Ensign Peak Advisors, Inc transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 21,643 shares of PRTA stock, worth $315,987. This represents 0.0% of its overall portfolio holdings.

Number of Shares

21,643

Previous 21,643 -0.0%

Holding current value

$315,987

Previous $446,000 18.83%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$19.54 - $26.15 $98,677 - $132,057	5,050 Added 30.43%	21,643 $446,000
Q1 2024 May 14, 2024	SELL	$24.75 - $40.66 $1.59 Million - $2.61 Million	-64,241 Reduced 79.47%	16,593 $411,000
Q4 2023 Feb 14, 2024	SELL	$32.31 - $52.32 $1.47 Million - $2.37 Million	-45,388 Reduced 35.96%	80,834 $2.94 Million
Q2 2023 Aug 14, 2023	BUY	$48.26 - $78.59 $28,956 - $47,154	600 Added 0.48%	126,222 $8.62 Million
Q1 2023 May 15, 2023	BUY	$46.97 - $58.27 $9,394 - $11,654	200 Added 0.16%	125,622 $6.09 Million
Q4 2022 Feb 13, 2023	BUY	$52.05 - $65.0 $3.31 Million - $4.14 Million	63,665 Added 103.09%	125,422 $7.56 Million
Q3 2022 Nov 14, 2022	BUY	$25.16 - $60.63 $298,900 - $720,284	11,880 Added 23.82%	61,757 $3.75 Million
Q1 2022 May 16, 2022	BUY	$30.27 - $49.22 $329,337 - $535,513	10,880 Added 27.9%	49,877 $1.82 Million
Q4 2021 Feb 11, 2022	BUY	$42.11 - $73.26 $708,921 - $1.23 Million	16,835 Added 75.96%	38,997 $1.93 Million
Q3 2021 Nov 12, 2021	BUY	$48.2 - $78.89 $218,538 - $357,687	4,534 Added 25.72%	22,162 $1.58 Million
Q3 2020 Nov 12, 2020	BUY	$9.93 - $13.47 $175,046 - $237,449	17,628 New	17,628 $176,000

Others Institutions Holding PRTA

# of Institutions

184

Shares Held

42.7M

Call Options Held

162K

Put Options Held

102K

View Full List

About PROTHENA CORP PUBLIC LTD CO

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $685M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

More about PRTA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ensign Peak Advisors, Inc with notifications on news.

Account

Ensign Peak Advisors, Inc Prothena Corp Public LTD CO Transaction History